Quantcast
Last updated on April 24, 2014 at 17:35 EDT

ArcDia International Ltd, the Multianalyte Point-of-Care Company for Infectious Diseases, Strengthens Management

April 11, 2013

TURKU, Finland, April 11, 2013 /PRNewswire/ –

ArcDia International Ltd, the manufacturer of world’s only multianalyte point-of-care
diagnostic system for respiratory tract infections, is pleased to announce the
strengthening of its management team and customer operations with the appointment of
Jesper Floyd Kristiansen as VP Sales and Marketing.

Prior the appointment, Mr. Kristiansen held various management positions at Dako, the
leading company for cancer diagnostics. He has worked as Business Director and Country
Manager responsible for P&L and sales operations in the Central East Europe, Russia and
Africa regions.

“ArcDia’s mariPOC(R) is the first and only product on the market to allow efficient
testing of infectious diseases at the point-of care. ArcDia has during the last couple of
years participated in the most relevant trade fairs and congresses, and as late as January
mariPOC(R) was presented at the Arab Health in Dubai with a huge interest from both
potential distributors and end-users. I am excited to join the ArcDia team and to expand
mariPOC(R) business in the international markets”, says Jesper Kristiansen, VP Sales and
Marketing, ArcDia Ltd.

“We are pleased to welcome Mr. Kristiansen to join the ArcDia team. He brings his
experience and knowledge in international sales of IVD products to build up the
distribution channels and customer operations for the mariPOC(R) product line”, says Dr.
Aleksi Soini, CEO of ArcDia Ltd.

Earlier in 2012, ArcDia announced collaboration agreement with Laboratories LETI for
Spain and Portugal. ArcDia’s products have been in daily clinical practice since 2011.

About mariPOC(R):

mariPOC(R)provides multianalyte diagnostic results for influenza like illnesses and
tonsillitis in near patient settings in 20 minutes. The mariPOC(R) applications are
targeted to acute respiratory infections, which represents the most common infectious
diseases on Earth.

mariPOC(R) is superior in performance to the conventional test methods, including
lateral flow rapid tests and standard culturing. mariPOC(R) is designed to improve patient
management, quality of health care, and to allow pathogen specific timely diagnostics and
medication to all patients. mariPOC(R) was launched to the European market in late 2010.

About ArcDia:

ArcDia International Ltd is the manufacturer of mariPOC(R), world’s first multianalyte
point-of-care diagnostics test for respiratory tract infections. In the future, the
company will develop additional point-of-care tests based on its proprietary ArcDia(TM)
TPX detection technology (Nature Biotech 2000:18). The technology is available for
prominent industrial parties for in-licensing. Currently, ArcDia is actively seeking
distribution partners for mariPOC(R). http://www.arcdia.com

SOURCE ArcDia International Ltd


Source: PR Newswire